Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Dapsone

Dapsone
In stock
1000caps
from 178,13 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
213,75 £178,13 £
178,13 £ per bottle

In brief

  • In our pharmacy, you can buy dapsone without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
  • Dapsone is used for leprosy (as part of multidrug therapy), dermatitis herpetiformis and (off-label) Pneumocystis jirovecii pneumonia prophylaxis; it is a sulfone that acts bacteriostatically by inhibiting dihydropteroate synthase (interfering with folate synthesis) and has anti‑inflammatory effects on neutrophil function.
  • The usual doses are: oral 100 mg once daily for leprosy (adult); dermatitis herpetiformis typically 50–100 mg daily (dose titrated); paediatric dosing is commonly weight‑based (about 1 mg/kg up to 50 mg daily).
  • Administration form: oral tablets (50 mg, 100 mg), also used within multidrug leprosy regimens.
  • Onset: systemic antimicrobial/clinical effects may take days to weeks, and leprosy treatment is assessed over months as part of MDT.
  • Duration of action: oral dapsone has a long elimination half‑life (around 20–30 hours) allowing once‑daily dosing; leprosy regimens continue for 6–24 months as indicated.
  • Avoid excessive alcohol while taking dapsone — alcohol may worsen liver-related adverse effects and general tolerance; also take care if you have liver disease or G6PD deficiency and consult a clinician before drinking alcohol with treatment.
  • The most common side effect is nausea; however, important adverse effects include haemolytic anaemia and methaemoglobinaemia (particularly in G6PD deficiency), rash and mild liver enzyme elevations.
  • Would you like to try dapsone without a prescription?

Basic dapsone information

  • INN (international nonproprietary name): dapsone (also known as diaminodiphenyl sulfone, DDS).
  • Brand names available in the United Kingdom: generic dapsone tablets.
  • ATC code: J04BA02 (antimycobacterials, drugs for treatment of lepra) and D10AX05 (dermatologicals, topical acne agent).
  • Forms and dosages: oral tablets 50 mg and 100 mg (topical dapsone gel is not licensed in the UK).
  • Registration status in the United Kingdom: prescription-only medicine (POM).
  • Classification: Prescription-only medicine (POM).
  • Typical adult dosages: Leprosy 100 mg once daily as part of multidrug therapy; dermatitis herpetiformis 50–100 mg daily titrated to response.
  • Dosage adjustments: Children weight‑based for leprosy (≈1 mg/kg up to 50mg), use caution in elderly, reduce or avoid with significant renal or hepatic impairment.
  • Missed dose: Take a missed dose as soon as remembered unless near next dose; do not double up.
  • Storage: Store at room temperature, protect from moisture and heat; do not freeze topical forms.
  • Absolute contraindications: Known hypersensitivity to dapsone or sulfone group, severe G6PD deficiency, acute anaemia or prior methemoglobinaemia, severe hepatic impairment.

Critical warnings and restrictions (patient safety first)

Dapsone can cause serious blood disorders such as haemolysis and methemoglobinaemia, so safety checks come first.

Patients must have G6PD status checked before any systemic dapsone is started.

Absolute contraindications include known sulfone allergy, severe G6PD deficiency, acute anaemia or previous methemoglobinaemia, and severe hepatic impairment.

Use extreme caution in elderly patients and in those with chronic renal or hepatic disease because accumulation increases risk of adverse effects.

Regular monitoring of full blood count and liver function tests is mandatory during systemic therapy.

Pregnancy and breastfeeding require specialist advice and a documented benefits‑versus‑risks discussion in the clinical record.

  • Pre‑treatment screening checklist: G6PD test, baseline full blood count (FBC), liver function tests (LFTs), and pregnancy test where applicable.

High-risk groups

Elderly people have a higher risk of toxicity and need closer monitoring when prescribed systemic dapsone.

Pregnancy requires specialist dermatology or obstetric input and clear documentation of counselling.

Patients with chronic renal or hepatic illness need individualised dosing decisions and frequent review of bloods.

Interaction with activities (driving, workplace safety under UK law)

Dizziness, visual disturbance or severe headache may occur with dapsone and can impair safe driving or use of machinery.

Under UK road and workplace safety rules, patients who feel affected must not drive or operate heavy machinery.

  • Stop driving and avoid machinery if you experience dizziness, marked visual changes, fainting, severe headache, or sudden breathlessness.
  • Seek urgent clinical advice or call NHS 111 if symptoms are severe or persistent.

Q&A — Can I drive after taking it in the UK?

Usually you may drive if you feel well and unaffected after taking dapsone.

If you experience dizziness, severe headache, cyanosis, visual disturbance or breathlessness you must not drive and should seek clinical advice or call 111 or your GP.

Persistent impairment should be reported to the DVLA where required and counselling notes should be kept in the pharmacy record.

Usage basics

INN, brand names available in the UK

The INN is dapsone, also listed as DDS in some formularies.

In the UK it is supplied as generic dapsone tablets (50 mg, 100 mg); topical dapsone gel is not licensed in the UK.

Legal classification

Dapsone is a prescription-only medicine (POM) in the UK and supply requires a valid prescription.

  • What you need to obtain a prescription: NHS or privately issued paper prescription, electronic prescription token sent to a nominated pharmacy, and ID where local pharmacy policy requires identification for private dispensing.

Dosing guide

Standard regimens (NHS guidelines)

For leprosy as part of multidrug therapy, typical adult oral dosing is 100mg once daily.

For dermatitis herpetiformis systemic dapsone is commonly started at 50–100mg daily and titrated to effect and tolerability.

  • Checklist: Indication, starting dose, monitoring schedule — confirm indication, start at the recommended dose, and arrange FBC and LFT monitoring at baseline and during treatment.

Adjustments for comorbidities

Use caution in renal or hepatic impairment because of risk of accumulation and methemoglobinaemia; dose reduction or specialist advice may be required.

Elderly patients may not require a formal starting dose change but have increased toxicity risk and must be monitored closely.

Severe G6PD deficiency is a contraindication to systemic use; mild deficiency may permit specialist‑led therapy with close monitoring.

  • Baseline tests: Full blood count (FBC), liver function tests (LFTs), renal function, and G6PD status prior to systemic therapy.

Q&A — What if I miss a dose?

For oral dapsone, take the missed dose as soon as remembered unless it is near the time for the next dose, and do not double doses to catch up.

If you miss doses repeatedly contact the GP or prescribing clinician to review adherence and monitoring.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

No major food–drug interactions require fasting with dapsone, but alcohol may worsen hepatic risk and exacerbate anaemia while starting systemic therapy.

Caffeine does not have a direct contraindication but counsel patients about possible worsening of dizziness or insomnia when combined with systemic side effects.

  • Practical advice: Avoid heavy alcohol while initiating systemic dapsone, maintain good hydration, and report new symptoms such as dark urine or breathlessness promptly.

Common drug conflicts

Dapsone interacts with oxidant drugs that increase the risk of haemolysis and methemoglobinaemia and with agents that alter hepatic metabolism.

Local anaesthetics that can produce methemoglobinaemia (for example prilocaine in susceptible patients) require caution with systemic dapsone.

Report suspected interactions and adverse reactions via the MHRA Yellow Card scheme and consult the BNF or local guidance before co‑prescribing.

Concomitant drug/class Interaction type Clinical action
Other oxidant drugs (e.g. certain sulfonamides) Increased haemolysis/methemoglobinaemia risk Avoid combination where possible; if necessary monitor FBC and methemoglobin symptoms closely.
Hepatic enzyme inducers (e.g. rifampicin) May alter dapsone levels via induction of metabolism Review therapeutic effect; adjust dose with specialist input and increase monitoring frequency.
Local anaesthetics (e.g. prilocaine) Increased methemoglobinaemia risk in susceptible patients Inform procedural teams, avoid in high‑risk patients or monitor oxygenation; consider alternative anaesthesia.

Legal status and availability in the UK

In our online pharmacy, dapsone is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Dapsone is a sulfone with both antimicrobial and anti‑inflammatory properties, acting primarily by inhibiting bacterial folate pathways and modulating neutrophil activity.

Topical dapsone reduces inflammatory lesions in acne by local anti‑inflammatory effects while systemic dapsone suppresses neutrophil‑mediated skin disease and acts bacteriostatically in leprosy.

  • Methaemoglobinaemia — Reduced oxygen‑carrying capacity caused by oxidation of haemoglobin to methaemoglobin.
  • Haemolysis — Destruction of red blood cells often provoked by oxidative stress, particularly in G6PD deficiency.

Clinical terms

Dapsone is orally well absorbed and undergoes hepatic metabolism with potential accumulation in hepatic or renal impairment.

Key clinical risks include haemolytic anaemia and methemoglobinaemia which are mechanistically linked to oxidative stress on red blood cells, especially in G6PD deficiency.

  • Monitoring parameters: Full blood count with reticulocyte count, liver function tests, renal function and methemoglobin measurement if symptoms suggestive of hypoxia occur.

Indications and off‑label uses

MHRA‑approved uses

In the UK, dapsone is licensed for leprosy and dermatitis herpetiformis.

Systemic use in dermatitis herpetiformis is standard in the UK under specialist care.

  • Licensed indications: Leprosy, dermatitis herpetiformis.

Off‑label practices in NHS and private care

Off‑label uses can include Pneumocystis jirovecii pneumonia (PCP) prophylaxis for patients intolerant of co‑trimoxazole, or selected dermatological indications after specialist review.

  • Off‑label checklist: Obtain documented informed consent, agree monitoring schedule, and involve specialist referral when needed.

Alternatives matrix

NHS prescribing alternatives

Drug/class Typical indication Pros Cons Monitoring
Co‑trimoxazole PCP prophylaxis Effective alternative to dapsone Risk of sulfa allergy and other adverse effects Renal function, blood counts as per local guidance
Rifampicin / clofazimine Leprosy MDT companion drugs Part of standard multidrug regimens Rifampicin drug interactions, clofazimine skin staining LFTs, baseline counselling on interactions
Tetracyclines / minocycline Acne Good anti‑inflammatory properties Photosensitivity, contraindicated in pregnancy/young children Advice on sun protection, LFTs if prolonged use
Topical retinoids / benzoyl peroxide Acne Established topical first‑line agents Irritation, not always suitable alone for inflammatory lesions Skin tolerance checks and topical counselling

Pros and cons checklist

  • Compare efficacy versus monitoring burden when choosing dapsone or an alternative.
  • Document allergy history, pregnancy/breastfeeding plans and patient preference in the record.
  • When dapsone is contraindicated (severe G6PD deficiency) select non‑oxidant alternatives and document rationale.

Common questions (clinic‑facing)

How is baseline monitoring done?

Baseline tests include FBC, LFTs, renal profile and G6PD before systemic dapsone; repeat FBC at 2–4 weeks then periodically as per local protocol.

How long before I see skin improvement?

Systemic treatment of dermatological diseases may require weeks of treatment and dose titration.

What are red‑flag symptoms?

Urgent assessment is required for sudden breathlessness, cyanosis, dark urine, jaundice or pronounced fatigue which may indicate haemolysis or methemoglobinaemia.

Can dapsone be used during pregnancy?

Use in pregnancy requires specialist review; benefits may outweigh risks in some situations but the decision should be documented and involve obstetric care.

  • Red flags and immediate actions: Sudden breathlessness, cyanosis, dark urine, jaundice, or collapse — attend A&E or call 999 for emergency care; for urgent but non‑life‑threatening concerns contact GP or NHS 111.

Registration and regulation

MHRA approval process

Dapsone is authorised for the UK market under MHRA regulation and prescribers should use licensed indications or document off‑label justification.

Adverse reactions should be reported through the MHRA Yellow Card scheme to support pharmacovigilance.

  • How to report an adverse reaction: Gather patient details, suspected drug, reaction description and submit via the Yellow Card website or app.

NHS prescribing framework

Prescribing should align with NICE and MHRA guidance where available and complex cases are managed by dermatology or infectious disease specialists.

Electronic prescribing and repeat dispensing are appropriate once monitoring is stable and monitoring schedules should be visible in shared care records.

  • GP responsibilities: Arrange baseline tests, schedule monitoring, adjust dose as needed, and communicate results and plans with pharmacists and specialists.

Storage and handling

UK household storage (cold/damp climate)

Store oral dapsone tablets at room temperature away from moisture and heat, ideally in a dry cabinet rather than the bathroom where humidity is high.

  • Storage checklist: Choose a cool, dry cupboard; keep out of reach of children and pets; check expiry dates before use; discard out‑of‑date supplies via pharmacy return.

Guidance from NHS and pharmacists

Advise safe disposal by returning unwanted medicines to a pharmacy for proper destruction and do not flush medicines down the sink or toilet.

  • Practical points: For winter damp homes avoid bathroom cabinet storage; for summer avoid leaving medicines in cars; for spills on skin wash with soap and water and seek advice if irritation persists.

Guidelines for proper use (counselling and safety)

UK pharmacist counselling style

Begin consultations by confirming the indication and reviewing allergy history including sulfonamide/sulfone allergies.

Ensure G6PD status is known for systemic therapy and explain the required monitoring schedule and who will arrange blood tests.

Discuss red‑flag symptoms, driving and workplace safety implications and safe storage at home.

  • Essential counselling points: Indication, dose and timing, common side effects, red flags (breathlessness, dark urine, jaundice), monitoring dates, and when to seek urgent care.

NHS patient safety advice

Emphasise adherence to laboratory monitoring and make clear actions for side effects such as stopping the drug and seeking urgent assessment for signs of haemolysis or methemoglobinaemia.

Encourage reporting side effects to MHRA and provide contact details for the prescribing clinician and pharmacy.

  • Patient information to provide: Indication; prescribed dose and duration; monitoring dates with contact details; emergency contacts including GP, 111 and A&E advice; Yellow Card reporting link.

Delivery across the United Kingdom

City Region Delivery Time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Glasgow Scotland 9–21 days
Manchester Greater Manchester 9–21 days
Leeds West Yorkshire 9–21 days
Edinburgh Scotland 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days
Bristol South West England 9–21 days
Newcastle North East England 9–21 days
Southampton South East England 9–21 days
Nottingham East Midlands 9–21 days

Related products